Alberta Cancer Exercise Dose in Colorectal Cancer

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Calgary

About this trial

The purpose of this pilot randomized, wait-list controlled study is to evaluate the effects of exercise dose in terms of frequency (1 vs. 2 days per week) in individuals on systemic treatment for colorectal cancer. The impact on the individual (physical function, quality of life, fatigue and other patient reported outcomes) as well as on health care utilization (cost to deliver, cost to individuals, savings and impact to the health care system) will be evaluated. In addition, assessments of immunological markers to better understand the biological impact of exercise dose on immunological markers will be explored.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults (≥18)

Have a primary biopsy-proven diagnosis of colon or rectal adenocarcinoma and undergoing adjuvant systemic treatment

Cleared for exercise (PAR-Q+)

Able to attend scheduled sessions

Disqualifiers

Participants who have completed adjuvant treatment for CRC

Unstable cardiopulmonary disease

Uncontrolled hypertension

Active infection

Trial design

Design model

Parallel

Treatments tested in this trial

  • Group Exercise Classes - Arm 1

    Behavioral

    Interventional arm 1 complete the supervised 60-min exercise classes for 12 weeks at low-to-moderate intensity, progressing individually (warm-up, aerobic intervals, multi-joint resistance, balance/flexibility cool-down), once-weekly. Sessions are delivered in-person by a CEP at the ACCCC Stride Centre. Attendance, RPE, and any modifications/adverse events are logged each session. In addition to exercise, 5 behaviour components will be covered throughout the program using an "Exercise and Educate" model, to support behaviour change. The trained instructor will build a positive motivational climate utilizing training in health coaching and motivational interviewing.

  • Group Exercise Classes - Arm 2

    Behavioral

    Interventional arm 2 complete the supervised 60-min exercise classes for 12 weeks at low-to-moderate intensity, progressing individually (warm-up, aerobic intervals, multi-joint resistance, balance/flexibility cool-down), twice-weekly. Sessions are delivered in-person by a CEP at the ACCCC Stride Centre. Attendance, RPE, and any modifications/adverse events are logged each session. In addition to exercise, 5 behaviour components will be covered throughout the program using an "Exercise and Educate" model, to support behaviour change. The trained instructor will build a positive motivational climate utilizing training in health coaching and motivational interviewing.

Treatment groups

90 Participants
are divided into 3 treatment groups
Group A: Once/week exercise session for 12 weeks (Arm 1)Experimental treatment 1 intervention
Group B: Twice/week exercise session for 12 weeks (Arm 2)Active comparator 1 intervention
Group C: Control-waitlisted group (Arm 3)No intervention 0 interventions

Trial outcomes

Primary outcomes

1

Proportion of patients in the once per week and twice per week group that achieve an increase of ≥10 MET-h/wk of total physical activity level at 12 weeks.

To assess the dose-response effect of exercise frequency (once versus twice weekly) over a 12-week period on clinically meaningful improvements in physical activity level (≥10 MET-h/wk increase over baseline) in patients with early-stage CRC receiving systemic treatment, with the goal of identifying the minimal effective intervention frequency

Time frame
Single time point: 12 weeks

Secondary outcomes

1

Number of participants with exercise-related adverse events with CTCAE standardized reports

To assess safety of the once per week versus twice per week supervised exercise

Time frame
From enrollment to 24 weeks
2

Difference in health economic and health care utilization between groups over 52 weeks

Indirect costs of cancer, work and productivity, time and income loss, informal care and daily impact, treatment attendance and travel, out-of-pocket costs, medications and cost for cancer treatment, emergency department admissions, and hospitalizations

Time frame
From enrollment to 52 weeks
3

Changes from baseline in the PROs at 12 weeks, and at 24- and 52-week follow-ups.

Assess changes in patient-reported outcomes (PROs) - including quality of life, functional abilities, cognitive function, well-being, fatigue, and symptoms - from the start of the study through the end of the intervention, and then at follow-up visits.

Time frame
From enrollment to the end of the study at 52 weeks
4

Changes from baseline in anthropometric parameters and fitness level at 12 weeks, and at the 24- and 52-week follow-ups.

Assess changes in anthropometric parameters (height and weight) and physical fitness - including cardiorespiratory fitness, musculoskeletal fitness, flexibility and balance - from the start of the study through the end of the intervention, and then at follow-up visits.

Time frame
From enrollment to the end of the study at 52 weeks

Other outcomes

1

Changes from baseline in immunologic parameters at 8 weeks and 12-week follow-up.

Explore biologic mechanisms of exercise through changes in peripheral immune cell composition, particularly T-cell subsets. These endpoints may clarify whether exercise dose is associated with immunologic changes relevant to CRC outcomes and patient-reported benefit.

Time frame
From enrollment to 8 and 12 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Calgary

Lead sponsor

Arthur J.E. Child Comprehensive Cancer Centre

Collaborator

This trial is not recruiting at the moment. You can still explore other options: